-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Cfek0fUppgEg2ofPySxbNoRopyQ8VzN4SuOoZFP+/8pomm+c1fKEbnCQp84Q/hmw yfRDNyo4yq4O1crBf757fA== 0000950123-09-013980.txt : 20090615 0000950123-09-013980.hdr.sgml : 20090615 20090615135155 ACCESSION NUMBER: 0000950123-09-013980 CONFORMED SUBMISSION TYPE: DEFA14A PUBLIC DOCUMENT COUNT: 5 FILED AS OF DATE: 20090615 DATE AS OF CHANGE: 20090615 EFFECTIVENESS DATE: 20090615 FILER: COMPANY DATA: COMPANY CONFORMED NAME: REGENERX BIOPHARMACEUTICALS INC CENTRAL INDEX KEY: 0000707511 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 521253406 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEFA14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-15070 FILM NUMBER: 09891630 BUSINESS ADDRESS: STREET 1: 3 BETHESDA METRO CENTER STREET 2: SUITE 700 CITY: BETHESDA STATE: MD ZIP: 20814 BUSINESS PHONE: 3019611992 MAIL ADDRESS: STREET 1: 3 BETHESDA METRO CENTER STREET 2: SUITE 700 CITY: BETHESDA STATE: MD ZIP: 20814 FORMER COMPANY: FORMER CONFORMED NAME: ALPHA 1 BIOMEDICALS INC DATE OF NAME CHANGE: 19950719 DEFA14A 1 c86743defa14a.htm DEFINITIVE A14A Definitive A14A
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the Securities
Exchange Act of 1934 (Amendment No.     )
Filed by the Registrant þ
Filed by a Party other than the Registrant o
Check the appropriate box:
o   Preliminary Proxy Statement
o   Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
o   Definitive Proxy Statement
þ   Definitive Additional Materials
o   Soliciting Material Pursuant to §240.14a-12
 
RegeneRx Biopharmaceuticals, Inc.
 
(Name of Registrant as Specified In Its Charter)
 
 
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
þ   No fee required.
o   Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
  (1)   Title of each class of securities to which transaction applies:
 
     
     
 
 
  (2)   Aggregate number of securities to which transaction applies:
 
     
     
 
 
  (3)   Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
 
     
     
 
 
  (4)   Proposed maximum aggregate value of transaction:
 
     
     
 
 
  (5)   Total fee paid:
 
     
     
 
o   Fee paid previously with preliminary materials.
 
o   Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
  (1)   Amount Previously Paid:
 
     
     
 
 
  (2)   Form, Schedule or Registration Statement No.:
 
     
     
 
 
  (3)   Filing Party:
 
     
     
 
 
  (4)   Date Filed:
 
     
     
 


 

*** Exercise Your Right to Vote ***
IMPORTANT NOTICE Regarding the Availability of Proxy Materials

REGENERX BIOPHARMACEUTICALS, INC.
REGENERX BIOPHARMACEUTICALS, INC.
3 BETHESDA METRO CENTER, STE. 630
BETHESDA, MD 20814
(NUMBERS)

Meeting Information
Meeting Type: Annual
For holders as of: 6/10/09
Date: 7/29/09      Time: 11:00 a.m.
Location:  
Cooley Godward Kronish LLP
One Freedom Square, 15th Floor
Reston Town Center
11951 Freedom Drive
Reston, VA 20190
You are receiving this communication because you hold
shares in the company named above.
This is not a ballot. You cannot use this notice to vote these shares. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. You may view the proxy materials online at www.proxyvote.com or easily request a paper copy (see reverse side).
We encourage you to access and review all of the important information contained in the proxy materials before voting.
See the reverse side of this notice to obtain proxy materials and voting instructions.


 

 


 

(NUMBERS)
Before You Vote
How to Access the Proxy Materials

Proxy Materials Available to VIEW or RECEIVE:
NOTICE AND PROXY STATEMENT      ANNUAL REPORT
How to View Online:
Have the 12-Digit Control Number available (located on the following page) and visit: www.proxyvote.com.
How to Request and Receive a PAPER or E-MAIL Copy:
If you want to receive a paper or e-mail copy of these documents, you must request one. There is NO charge for requesting a copy. Please choose one of the following methods to make your request:
     
1) BY INTERNET:
  www.proxyvote.com
2) BY TELEPHONE:
  1-800-579-1639
3) BY E-MAIL*:
  sendmaterial@proxyvote.com
     
*  
If requesting materials by e-mail, please send a blank e-mail with the 12-Digit Control Number (located on the following page) in the subject line.
Requests, instructions and other inquiries sent to this e-mail address will NOT be forwarded to your investment advisor. To facilitate timely delivery, please make the request as instructed above on or before 7/15/09.
How To Vote
Please Choose One of the Following Voting Methods

Vote In Person: Many stockholder meetings have attendance requirements including, but not limited to, the possession of an attendance ticket issued by the entity holding the meeting. Please check the meeting materials for any special requirements for meeting attendance. At the meeting, you will need to request a ballot to vote these shares.
Vote By Internet: To vote now by Internet, go to www.proxyvote.com. Have the 12-Digit Control Number available and follow the instructions.
Vote By Mail: You can vote by mail by requesting a paper copy of the materials, which will include a proxy card.


 

 


 

Voting Items
The Board of Directors recommends a vote “FOR” each of the nominees for Director and “FOR” Proposal 2.
   
  1.  
Election of Directors
Nominees:
01) J.J. Finkelstein
  04) L. Thompson Bowles
02) Allan L. Goldstein
  05) Richard J. Hindin
03) Joseph C. McNay
  06) Mauro Bove
  2.  
Ratify the selection by the Audit Committee of Reznick Group, P.C., as the Independent Registered Public Accounting Firm for RegeneRx Biopharmaceuticals, Inc., for the fiscal year ending December 31, 2009.
(NUMBERS)

 

 


 

 

 

 

 
 
(NUMBERS)

 

 

GRAPHIC 2 c86743c8674301.gif GRAPHIC begin 644 c86743c8674301.gif M1TE&.#EA#`!,`+,.`)"0D*"@H+"PL'!P<.#@X%!04&!@8#`P,"`@($!`0-#0 MT/#P\("`@,#`P/___P```"'Y!`$```X`+``````,`$P```3]T,E):ZCX,-:P M3%*S+15(D12@>&Q[5EO,54!CWQ7J[I>KS1Z3B*'[Y&BKW:Z!`A0="0/C`IP< M)`M`53)`+1*="F&R&+,43P>C(!@D!AB!`W!UA"'LL%"?GYG9&XWD_!C%TJ06T#K`HBDEB#5,U% 5``3(`B0@A4<#BG:M8C@3Q=%!!``[ ` end GRAPHIC 3 c86743c8674302.gif GRAPHIC begin 644 c86743c8674302.gif M1TE&.#EA#`!,`+,.`*"@H)"0D.#@X-#0T+"PL'!P<%!04#`P,&!@8"`@($!` M0/#P\("`@,#`P/___P```"'Y!`$```X`+``````,`$P```3\T,E)*ZCX,-:P M5%*S+15(D50P>&Q[5EO,54%CWQ7J[I>KS1Z3B*'[Y&BKW:Z!"A0="@3C`IP< M)(M`55)`+12=BF"R&+,&3P?#0"@H"AB"(W!UA"<`0<))2$X("F@&#$H8`P9P M+`@$`3UQ$G(.3S4--01W$H,Q!9@.9A.?%0..'B(NHX6I%``&`@<*I)ESA`*A M#CUC-CDZ3*HL3S(;G90WG6F^8J4W"+T4!5(,"@RV#@-RA"T`",@A$@%.&"`% M'`$8!@MU#7Y8`.6WG GRAPHIC 4 c86743c8674303.gif GRAPHIC begin 644 c86743c8674303.gif M1TE&.#EA#`!,`+,.`-#0T)"0D+"PL*"@H.#@X'!P<&!@8%!04#`P,"`@($!` M0/#P\,#`P("`@/___P```"'Y!`$```X`+``````,`$P```3\T,E)ZZ@8M<:P M5!*S+15(D50`>&Q[5EO,50%CWQ7J[I>KS1Z3J*'[Y&BKW8Z!"A0="D/C`IP@ M)(M`55)`+12="F&R&+,`3T?C("@H"AB!(W!UA"<#0L(I2$X$"F@'#4H8``=P M+`8"`3UQ$G(.3S4,-0)W$H,Q!9@.9A.?%0".'B(NHX4NG1(R"@VA#@(<#`9, M&`L"!(0MIJDN3S(;G90WG6F^&+`A-[5/!5(-KLH` GRAPHIC 5 c86743c8674304.gif GRAPHIC begin 644 c86743c8674304.gif M1TE&.#EA#`!,`+,.`-#0T*"@H)"0D+"PL.#@X'!P<#`P,&!@8%!04"`@($!` M0/#P\("`@,#`P/___P```"'Y!`$```X`+``````,`$P```3]T,E):ZC8,-:P M5%*S+15(D90`>&Q[5EO,54)CWQ7J[I>KS1Z3B*'[Y&BKW:Z!$A0=B@/C`IP8 M)`M!55)`+12="F&R&+,`3P<#,2@H"IB!0W!UA"=:<`8MR$W![\4!5(,LMP@*^/B=D1/L2D_"CO%R%6L#)PPBDC"#Q&`A 5G@3)8)'"HV%5A03D-CP3Q=%!!``[ ` end
-----END PRIVACY-ENHANCED MESSAGE-----